Development of preclinical and clinical models for immune-related adverse events following checkpoint immunotherapy: a perspective from SITC and AACR

• Theresa L Walunas,
• Lisa H Butterfield,
• William J Murphy,
• Elizabeth M Jaffee,
• Bart O Roep,
• Nicholas L Bayless,
• Jeffrey A Bluestone,
• Samantha Bucktrout,
• Christian A Koch,
• Arlene H Sharpe

Affiliations

Theresa L Walunas

Division of General Internal Medicine and Geriatrics, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA

Lisa H Butterfield

Aff1 grid.478063.e0000000404569819University of Pittsburgh Cancer Institute PA USA

William J Murphy

Aff1 grid.413079.80000000097528549Department of DermatologyUniversity of California, Davis Medical Center Sacramento CA USA

Elizabeth M Jaffee

Aff2 grid.21107.350000000121719311Sidney Kimmel Cancer CenterJohns Hopkins University Baltimore MD USA

Bart O Roep

Department of Immunohematology and Blood Transfusion, Leiden University Medical Center, Leiden, The Netherlands

Nicholas L Bayless

Parker Institute for Cancer Immunotherapy, San Francisco, California, USA

Jeffrey A Bluestone

Diabetes Center, University of California San Francisco, San Francisco, California, USA

Samantha Bucktrout

Parker Institute for Cancer Immunotherapy, San Francisco, California, USA

Christian A Koch

Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA

Arlene H Sharpe

Department of Immunology, Blavatnik Institute, Harvard Medical School and Evergrande Center for Immunologic Diseases, Harvard Medical School, Boston, Massachusetts, USA